Junshi Bio Invests $43 Million to Partner Impact’s PARP Inhibitor in China

On August 20, 2020 Junshi Biosciences, a Shanghai biopharma, reported a JV with Nanjing’s Impact Therapeutics to develop Impact’s PARP inhibitor (Press release, ChinaBio, AUG 20, 2020, View Source [SID1234563932]). Junshi will contribute $43 million for 50% of the JV while Impact will add Greater China rights to IMP4297, the company’s clinical-stage PARP inhibitor. The two companies will collaborate on conducting clinical trials of the candidate in multiple indications, starting with ovarian cancer, plus preparing for manufacturing and commercialization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021

On August 20, 2020 Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) reported the successful placement of the 1.00% qualified subordinated mandatory convertible bond 2020/2021 with gross proceeds of EUR 7.9 million (Press release, Biofrontera, AUG 20, 2020, View Source [SID1234568551]). Within the scope of the issuance, 2,638,150 qualified subordinated mandatory convertible bearer bonds (the "Bond") were issued . The subscription price equaled 100% of the nominal value, corresponding to EUR 3.00 per Bond.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The mandatory convertible bond 2020/2021, with the German Securities Identification Number A3E454 / ISIN DE000A3E4548, matures on December 20, 2021 and has been admitted for trading on the Open Market of the Frankfurt Stock Exchange as of today, August 20, 2020.

According to Section 8 (2) of the terms and conditions of the mandatory convertible bond 2020/2021, the issuer Biofrontera AG, has, for an unlimited period of time, the right of "mandatory conversion" any time after the stock price of Biofrontera’s shares (ISIN: DE0006046113) has exceeded EUR 4.50 at least once ("Mandatory Conversion Trigger Price"). The relevant stock price shall be the daily volume-weighted average quotation of the issuer’s shares determined on the XETRA trading platform of the Frankfurt Stock Exchange within a continuous period of fifteen trading days. The Mandatory Conversion Trigger Price has already been exceeded as of today according to the calculation described above, and the relevant average price stands at EUR 4.8350. The issuer reserves the right to decide at what point in time it will exercise its right of mandatory conversion and will select the most appropriate time to do so after taking into account all foreseeable circumstances. According to Section 16 of the terms and conditions of the mandatory convertible bond, the request for mandatory conversion will be published in the Federal Gazette as well as via a corporate news release.

BiondVax Announces Second Quarter 2020 Financial Results

On August 20, 2020 BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, reported its second quarter financial results for the quarter ended June 30, 2020 (Press release, BiondVax Pharmaceuticals, AUG 20, 2020, View Source [SID1234563912]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Second Quarter 2020 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.466 (NIS/$US) as at June 30, 2020.

Total operating expenses for the second quarter were NIS 16.0 million (approximately $4.61 million) compared with NIS 19.7 million for the second quarter of 2019.

R&D expenses for the second quarter amounted to NIS 11.9 million (approximately $3.4 million) compared with NIS 15.2 million for the second quarter of 2019.
Net loss for the second quarter was NIS 42 million (approximately $12.1 million) compared to net loss of NIS 47.4 million for the second quarter of 2019.
The decrease in total operating expenses compared to the second quarter of 2019 was primarily due to fewer costs associated with the nearly complete pivotal Phase 3 trial and completion of construction of the manufacturing facility.

As of June 30, 2020, BiondVax had cash and cash equivalents of NIS 38.7 million (approximately $11.2 million) compared to NIS 72.4 million as of December 31, 2019.

Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

On August 20, 2020 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, reported it will conduct a conference call with investors to review financial results of its second quarter and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson (Press release, Can-Fite BioPharma, AUG 20, 2020, View Source [SID1234563895]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Call Information

Date: Thursday, August 27, 2020

Time: 4:15 p.m. ET

Dial-in U.S.: 1-877-423-9813

Dial-in Israel: 1-201-689-8573

Conference ID: 13708494

Audio Webcast: View Source

A press release reviewing the second quarter results and clinical updates will be issued prior to the call. A replay of the webcast will be archived on Can-Fite’s website for a period of time.

Immunovia Reports Second Quarter Interim Report January – June 2020

On August 20, 2020 Immunovia reported that published second quarter interim report for January – June 2020 (Press release, Immunovia, AUG 20, 2020, View Source;june-2020-301115788.html [SID1234563913]). It is available on Immunovia’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During Q2, we successfully handled COVID-19 challenges beyond our control, strengthened

the company’s economic position, began the expansion of our sales, marketing, and customer service organizations, and are now, despite the COVID-19 pandemic, aiming to launch the first-ever test for early detection of pancreatic cancer during Q4 2020.

During the entire quarter, we provided continuous updates on our focused measures to minimize the impact of the COVID-19 pandemic on our employees, the company, and our commercialization efforts. As we announced in May, we were forced to adjust the company’s timeline and launch date for IMMray PanCan-d to Q4 2020, due to the shutdown of the state of Massachusetts, which directly impacted important activities at our laboratory in Marlborough, MA. We were able to reopen the Marlborough laboratory on May 25, 2020, and we have since been able to continue working with the greatest possible speed, energy, and enthusiasm.

On June 4th, we successfully implemented one of the largest capital raises ever for a non-

USA-based diagnostic company. Immunovia announced a directed new share issue of approximately SEK 400 million. The capital from this new directed share issue is now being used for commercialization activities in conjunction with the launch of IMMray PanCan-d, our top priority. This capital raise allows Immunovia to take the next step in establishing itself as a world leader in the early detection of complex illnesses such as cancer and autoimmune disease. It also allows the company to be more resilient against any market volatility and ensures that we can fully commit to our launch preparations and commercialization.

We ended the quarter with our first virtual investment day, which included presentations by Immunovia’s chairman, Carl Borrebaeck; VD, Mats Grahn; Chief Commercial Officer, Laura Chirica; Senior VP Sales North America, Michael Pettigrew; and Dr. Thomas King, Medical Director as well as a comprehensive and interactive Q&A session with Immunovia’s stakeholders. A highlight of the event was a virtual tour of our Marlborough laboratory. A recording of the event can be found on our website.

On behalf of the board and the entire Immunovia team, we thank you for your continued support of Immunovia’s effort to positively impact the lives of those at risk of pancreatic cancer. We are launching IMMray PanCan-d in Q4 of this year!."

– Excerpt from the CEO Mats Grahn’s comment on the report

Seond Quarter Interim Report for January – June 2020 Call Details:

Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, August 20, 2020 at 16:30 CET.

Mats Grahn, CEO will present Immunovia and comment on the second quarter interim report for the period January – June 2020 followed by a Q&A session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Conference Code: (to provide to the operator) Immunovia

Immunovia Webcast:https://channel.royalcast.com/immunovia/#!/immunovia/20200820_1

For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Email: [email protected]

Tel: +46 7 93 486 277

There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (View Source) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:00 CET on August 20, 2020.